Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Good financial results growth rate 13.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-4.0%)
  • Dividend yield for the last twelve months 1.8%
  • Free cash flow yield 0.6% (LTM)
  • Share price is 42.5% higher than minimum and 8.3% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (26.0x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.7 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (+0.7%)128.54
year average price 127.22  


year start price 119.39 2024-10-19

min close price 111.10 2025-01-15

max close price 140.22 2025-03-03

current price 128.54 2025-10-18
Common stocks: 1 746 881 140

Dividend Yield:  1.8%
FCF Yield LTM: 0.6%
EV / LTM EBITDA: 26.0x
EV / EBITDA annualized: 24.0x
Last revenue growth (y/y):  +7.4%
Last growth of EBITDA (y/y):  +20.3%
Historical revenue growth:  -1.5%
Historical growth of EBITDA:  -6.6%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap (mln): 224 544
Net Debt (mln): 6 430
EV (Enterprise Value): 230 974
EBITDA LTM (mln): 8 881
EV / LTM EBITDA: 26.0x
Price to Book: 5.6x

Revenue and EBITDA

Quarterly values (mln)

Change (y/y)

Cash Flow

FCF (mln)

Net Debt / Cash and Equivalents (mln)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-10-17247wallst.com

Goldman Sachs 4 New Conviction List Stocks Offer Dividends and Growth

2025-10-15seekingalpha.com

Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript

2025-10-15zacks.com

Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs

2025-10-15zacks.com

Abbott (ABT) Q3 Earnings Meet Estimates

2025-10-15reuters.com

Abbott posts higher quarterly revenue on strong medical device demand

2025-10-12seekingalpha.com

Wall Street Week Ahead

2025-10-10zacks.com

Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings

2025-10-09seekingalpha.com

Abbott Laboratories: There May Be A Surge Coming Next Week (Earnings Preview)

2025-10-03zacks.com

Abbott (ABT) Laps the Stock Market: Here's Why

2025-09-30proactiveinvestors.com

Healthcare equipment stocks seen outperforming, ‘safer' than Big Pharma: analysts
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data